As the pioneer and leading precision medicine innovator, Caris provides the most advanced and complete tumor profiling enhanced by artificial intelligence, yielding molecular insights that guide more personalized treatment decisions, improve patient outcomes and save lives.
With the promise of precision medicine becoming a reality, molecular profiling has become standard of care for many cancer types – and required for certain therapies. More than ever, oncologists need a trusted profiling partner to provide reliable, high quality molecular information to guide precise and individualized treatment decisions.
Caris molecular profiling utilizes a complete approach to assess DNA, RNA, and proteins to reveal the highest quality molecular blueprint and provide evidence-based selection of the most appropriate cancer therapy.
Caris tissue-based profiling utilizes the most advanced technologies and comprehensive approach to analyze DNA, RNA and proteins to reveal a molecular blueprint that guides more precise and individualized treatment decisions that leads to improved patient outcomes.
Caris utilizes comprehensive multi-omic biomarker analysis to assess DNA, RNA and proteins in a patient’s tumor, including more than 23,000 genes (DNA) and transcripts (RNA), 13+ tumor-expressed antigens (proteins), plus multiple genomic signatures and other analytical techniques.
Caris molecular profiling identifies key molecular features of cancer and provides clinical insights to aid oncologists in personalizing cancer therapies for their solid tumor cancer patients.
Our data-driven, molecular insights are changing the landscape of precision medicine with actionable insights from retrospective, epidemiologic, and real-time molecular data to enhance research and commercial activities.
Place an order today for a comprehensive, personalized Caris profiling report.